Treatment Guidelines for Retinoblastoma
Retinoblastoma management in 2025 prioritizes multimodality eye-salvage approaches using chemotherapy (intravenous, intra-arterial, or intravitreal) combined with focal consolidation therapies, with enucleation reserved for advanced intraocular disease and systemic chemotherapy plus radiotherapy for extraocular extension. 1, 2
Initial Assessment and Classification
The International Classification of Retinoblastoma (ICRB) staging system guides treatment decisions and must include documentation of hereditary disease status through germline RB1 testing for all children with retinoblastoma, regardless of laterality at presentation. 3, 4 Key pathologic features requiring assessment include:
- Growth pattern (unifocal, multifocal, or diffuse) and bilaterality status 5
- Optic nerve invasion by layer (prelaminar, laminar, retrolaminar, or to resection margin) 5
- Choroidal invasion as a potential metastatic risk factor 5
- Extraocular extension and vitreous/subretinal seeding 5
Intraocular Disease Management
Group A-C Disease (Lower Risk)
Primary treatment consists of focal consolidation therapies including cryotherapy for anterior tumors, transpupillary thermotherapy (TTT) for posterior tumors ≤3mm, and laser photocoagulation. 1, 4 For tumors requiring additional control, intravenous chemoreduction (typically carboplatin, etoposide, and vincristine) followed by focal consolidation achieves high globe salvage rates. 4, 6
Group D Disease (Advanced Intraocular)
Intra-arterial chemotherapy (IAC) via selective ophthalmic artery catheterization has become the preferred eye-salvage approach for advanced intraocular disease, demonstrating superior globe preservation compared to systemic chemotherapy. 7, 8 The procedure involves selective catheterization of the ophthalmic artery for delivering melphalan (primary agent), topotecan, or carboplatin. 7
For vitreous seeding, intravitreal chemotherapy with melphalan (20-30 μg in 0.1 mL) is now standard, using a strict injection technique to prevent extraocular tumor dissemination: inject 1.5-2mm posterior to limbus with immediate cryotherapy to needle tract, followed by paracentesis to normalize intraocular pressure. 8, 4, 2
For anterior chamber seeding, intracameral chemotherapy with melphalan (10-20 μg) provides targeted treatment. 4, 2
Group E Disease (Very Advanced)
Enucleation remains the primary treatment when globe salvage is not feasible, ensuring adequate optic nerve length (≥10mm when possible). 4, 6 Post-enucleation histopathologic examination determines need for adjuvant chemotherapy based on high-risk features:
- Retrolaminar optic nerve invasion (especially to resection margin)
- Massive choroidal invasion (>3mm diameter)
- Anterior chamber involvement
- Scleral invasion 5, 6, 9
Adjuvant systemic chemotherapy is mandatory for high-risk histopathologic features to address micrometastatic disease, typically using carboplatin, etoposide, and vincristine for 4-6 cycles. 6, 9
Extraocular Disease Management
Orbital Disease
For orbital extension without distant metastases, treatment requires intensive multimodality therapy:
- Neoadjuvant chemotherapy (6-9 cycles of carboplatin, etoposide, vincristine, with or without doxorubicin and cyclophosphamide) 9
- Orbital radiotherapy (40-45 Gy) following chemotherapy response 9
- Surgical resection if residual disease persists after chemoradiotherapy 9
Metastatic Disease
Metastatic retinoblastoma carries poor prognosis (50-70% survival) and requires high-dose chemotherapy protocols. 6, 9 Treatment includes:
- Intensive multi-agent chemotherapy with carboplatin, etoposide, vincristine, cyclophosphamide, and doxorubicin 9
- Consideration of high-dose chemotherapy with autologous stem cell rescue for selected cases 9
- Intrathecal chemotherapy for CNS involvement 9
Radiation Therapy Considerations
External beam radiotherapy (EBRT) is avoided when possible due to increased risk of secondary malignancies in hereditary retinoblastoma (particularly sarcomas in the radiation field), but remains an option for bilateral disease when other modalities fail. 4, 6 When radiation is necessary:
- Plaque brachytherapy (40-45 Gy) is preferred over EBRT for localized tumors, minimizing radiation exposure to surrounding tissues 4
- Minimize fluoroscopy time and dose-area product during procedures, especially in children with hereditary disease who face increased carcinogenic risk from ionizing radiation 7
Surveillance and Long-term Follow-up
For hereditary retinoblastoma survivors, surveillance focuses on secondary malignancy detection rather than routine imaging, as evidence supporting asymptomatic screening is lacking. 10 Recommended surveillance includes:
- Regular skin examination for melanoma detection 10
- Prompt evaluation of head and neck symptoms given increased sarcoma risk 10
- Genetic counseling regarding reproductive risks and screening of at-risk family members 3, 1
Critical Pitfalls to Avoid
Never perform intravitreal chemotherapy without proper technique (cryotherapy to needle tract, paracentesis) as this risks extraocular tumor seeding and dramatically worsens prognosis. 8, 4
Do not delay enucleation in Group E eyes attempting futile salvage therapies, as this increases risk of extraocular extension and metastatic disease. 4, 6
Always obtain germline RB1 testing even in unilateral cases, as 15% harbor germline mutations requiring different surveillance and family counseling. 3, 1
In developing countries with delayed presentation, recognize that extraocular disease predominates and requires aggressive multimodality treatment rather than eye-salvage approaches. 11, 9